Technical Analysis for LJPC - La Jolla Pharmaceutical Company

Grade Last Price % Change Price Change
F 4.07 -2.63% -0.11
LJPC closed down 2.63 percent on Friday, April 16, 2021, on 62 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical LJPC trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion -2.63%
Up 3 Days in a Row Strength -2.63%
MACD Bullish Signal Line Cross Bullish -0.73%
Narrow Range Bar Range Contraction -0.73%
NR7 Range Contraction -0.73%
Wide Bands Range Expansion -0.73%
Oversold Stochastic Weakness -0.73%
Hammer Candlestick Bullish 1.24%
Older End-of-Day Signals for LJPC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company's products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Medication Monoclonal Antibody Kidney Disease Chronic Kidney Disease Proteins Peptide Hormones Lectins Organ Failure Galectin Galectin 3 Hepatorenal Syndrome Renin Angiotensin

Is LJPC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.1
52 Week Low 3.3569
Average Volume 291,306
200-Day Moving Average 4.60
50-Day Moving Average 5.25
20-Day Moving Average 4.33
10-Day Moving Average 4.10
Average True Range 0.29
ADX 28.08
+DI 14.60
-DI 26.20
Chandelier Exit (Long, 3 ATRs ) 4.73
Chandelier Exit (Short, 3 ATRs ) 4.67
Upper Bollinger Band 5.02
Lower Bollinger Band 3.64
Percent B (%b) 0.31
BandWidth 31.82
MACD Line -0.31
MACD Signal Line -0.34
MACD Histogram 0.0265
Fundamentals Value
Market Cap 111.44 Million
Num Shares 27.4 Million
EPS -5.92
Price-to-Earnings (P/E) Ratio -0.69
Price-to-Sales 4.47
Price-to-Book 0.00
PEG Ratio -0.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.30
Resistance 3 (R3) 4.32 4.26 4.26
Resistance 2 (R2) 4.26 4.21 4.25 4.24
Resistance 1 (R1) 4.17 4.17 4.14 4.15 4.23
Pivot Point 4.11 4.11 4.10 4.10 4.11
Support 1 (S1) 4.02 4.06 3.99 4.00 3.91
Support 2 (S2) 3.96 4.02 3.95 3.90
Support 3 (S3) 3.87 3.96 3.88
Support 4 (S4) 3.85